Expression of TERRA in Different Grades of Astrocytoma

Document Type : Original Article(s)

Authors

1 Pediatric Inherited Diseases Research Center, Research Institute for Primordial Prevention of Non-communicable Disease AND Department of Genetics and Molecular Biology, School of Medicine, Isfahan University of Medical Sciences, Isfahan, Iran

2 Assistant Professor, Pediatric Inherited Diseases Research Center, Research Institute for Primordial Prevention of Non-communicable Disease AND Department of Genetics and Molecular Biology, School of Medicine, Isfahan University of Medical Sciences, Isfahan, Iran

Abstract

Background: Brain tumors include burden of mortality from cancers. High grades of brain tumors are more aggressive and have poor prognosis. Introduction telomeres are the ends of linear chromosomes that serve as a protective cap to avoid permanent proliferation arrest, termed replicative senescence. In vertebrates, telomeres consist of tandem repeats of TTAGGG hexanucleotide sequences. In spite of heterochromatin structure of telomeres, they are transcribed into a non-coding RNA called telomeric repeat-containing RNA or TERRA which acts as a natural inhibitor of telomerase activity. Considering astrocytoma, as one of the most common tumors of the central nervous system (CNS), and a very poor prognosis tumor, the aim of this study was to evaluate the TERRA expression level in astrocytoma tumors and nontumoral controls. Furthermore, expression levels of TERRA were compared between different grades of astrocytoma.Methods: The mRNA of 26 brain tumor samples and 4 samples as nontumoral controls were extracted and cDNA was synthesized. Then, real-time reverse transcription polymerase chain reaction (SYBR Green kit) for quantitation of total TERRA levels was developed.Findings: We demonstrated the correlation between total TERRA levels of expression with different grades of astrocytoma. High grades (III and IV) of astrocytoma tumors had lower mean of ∆Ct than low grades (II) and down-regulation for TERRA mRNA was 4.377-fold (P = 0.036). Additionally, measurement of TERRA expression in astrocytoma showed 4.969-fold less compared to levels of TERRA expression in nontumoral controls (P = 0.029).Conclusion: According to our study, TERRA may be prognostic marker in astrocytoma tumors. 

Keywords

References

  1. Blackburn EH. Structure and function of telomeres. Nature 1991; 350(6319): 569-73.
  2. Samassekou O, Gadji M, Drouin R, Yan J. Sizing the ends: normal length of human telomeres. Ann Anat 2010; 192(5): 284-91.
  3. Sampl S, Pramhas S, Stern C, Preusser M, Marosi C, Holzmann K. Expression of telomeres in astrocytoma WHO grade 2 to 4: TERRA level correlates with telomere length, telomerase activity, and advanced clinical grade. Transl Oncol 2012; 5(1): 56-65.
  4. Chen HJ, Liang CL, Lu K, Lin JW, Cho CL. Implication of telomerase activity and alternations of telomere length in the histologic characteristics of intracranial meningiomas. Cancer 2000; 89(10): 2092-8.
  5. Cabuy E, de Ridder L. Telomerase activity and expression of telomerase reverse transcriptase correlated with cell proliferation in meningiomas and malignant brain tumors in vivo. Virchows Arch 2001; 439(2): 176-84.
  6. Colgin LM, Reddel RR. Telomere maintenance mechanisms and cellular immortalization. Curr Opin Genet Dev 1999; 9(1): 97-103.
  7. Hanahan D, Weinberg RA. The hallmarks of cancer. Cell 2000; 100(1): 57-70.
  8. Shay JW, Bacchetti S. A survey of telomerase activity in human cancer. Eur J Cancer 1997; 33(5): 787-91.
  9. Neumann AA, Reddel RR. Telomere maintenance and cancer -- look, no telomerase. Nat Rev Cancer 2002; 2(11): 879-84.
  10. Henson JD, Neumann AA, Yeager TR, Reddel RR. Alternative lengthening of telomeres in mammalian cells. Oncogene 2002; 21(4): 598-610.
  11. Hakin-Smith V, Jellinek DA, Levy D, Carroll T, Teo M, Timperley WR, et al. Alternative lengthening of telomeres and survival in patients with glioblastoma multiforme. Lancet 2003; 361(9360): 836-8.
  12. Henson JD, Hannay JA, McCarthy SW, Royds JA, Yeager TR, Robinson RA, et al. A robust assay for alternative lengthening of telomeres in tumors shows the significance of alternative lengthening of telomeres in sarcomas and astrocytomas. Clin Cancer Res 2005; 11(1): 217-25.
  13. Henson JD, Reddel RR. Assaying and investigating Alternative Lengthening of Telomeres activity in human cells and cancers. FEBS Lett 2010; 584(17): 3800-11.
  14. Costa A, Daidone MG, Daprai L, Villa R, Cantu S, Pilotti S, et al. Telomere maintenance mechanisms in liposarcomas: association with histologic subtypes and disease progression. Cancer Res 2006; 66(17): 8918-24.
  15. Cairney CJ, Hoare SF, Daidone MG, Zaffaroni N, Keith WN. High level of telomerase RNA gene expression is associated with chromatin modification, the ALT phenotype and poor prognosis in liposarcoma. Br J Cancer 2008; 98(8): 1467-74.
  16. Ohali A, Avigad S, Ash S, Goshen Y, Luria D, Feinmesser M, et al. Telomere length is a prognostic factor in neuroblastoma. Cancer 2006; 107(6): 1391-9.
  17. Azzalin CM, Reichenbach P, Khoriauli L, Giulotto E, Lingner J. Telomeric repeat containing RNA and RNA surveillance factors at mammalian chromosome ends. Science 2007; 318(5851): 798-801.
  18. Feuerhahn S, Iglesias N, Panza A, Porro A, Lingner J. TERRA biogenesis, turnover and implications for function. FEBS Lett 2010; 584(17): 3812-8.
  19. Luke B, Panza A, Redon S, Iglesias N, Li Z, Lingner J. The Rat1p 5' to 3' exonuclease degrades telomeric repeat-containing RNA and promotes telomere elongation in Saccharomyces cerevisiae. Mol Cell 2008; 32(4): 465-77.
  20. Luke B, Lingner J. TERRA: telomeric repeat-containing RNA. EMBO J 2009; 28(17): 2503-10.
  21. Schoeftner S, Blasco MA. Chromatin regulation and non-coding RNAs at mammalian telomeres. Semin Cell Dev Biol 2010; 21(2): 186-93.
  22. Ng LJ, Cropley JE, Pickett HA, Reddel RR, Suter CM. Telomerase activity is associated with an increase in DNA methylation at the proximal subtelomere and a reduction in telomeric transcription. Nucleic Acids Res 2009; 37(4): 1152-9.
  23. Schoeftner S, Blasco MA. Developmentally regulated transcription of mammalian telomeres by DNA-dependent RNA polymerase II. Nat Cell Biol 2008; 10(2): 228-36.
  24. Hung NA, Hsia H, Royds JA, Slatter TL. Telomere maintenance mechanisms: prognostic and therapeutic implications for the pathologist and oncologist. Open Journal of Pathology 2013; 3(1): 10-20.
  25. Heaphy CM, Subhawong AP, Hong SM, Goggins MG, Montgomery EA, Gabrielson E, et al. Prevalence of the alternative lengthening of telomeres telomere maintenance mechanism in human cancer subtypes. Am J Pathol 2011; 179(4): 1608-15.
  26. Basu N, Skinner HG, Litzelman K, Vanderboom R, Baichoo E, Boardman LA. Telomeres and telomere dynamics: relevance to cancers of the GI tract. Expert Rev Gastroenterol Hepatol 2013; 7(8): 733-48.
  27. Ohgaki H, Kleihues P. Population-based studies on incidence, survival rates, and genetic alterations in astrocytic and oligodendroglial gliomas. J Neuropathol Exp Neurol 2005; 64(6): 479-89.
  28. Buckner JC, Brown PD, O'Neill BP, Meyer FB, Wetmore CJ, Uhm JH. Central nervous system tumors. Mayo Clin Proc 2007; 82(10): 1271-86.
  29. Scheithauer BW, Fuller GN, VandenBerg SR. The 2007 WHO classification of tumors of the nervous system: controversies in surgical neuropathology. Brain Pathol 2008; 18(3): 307-16.
  30. O'Callaghan N, Dhillon V, Thomas P, Fenech M. A quantitative real-time PCR method for absolute telomere length. Biotechniques 2008; 44(6): 807-9.
  31. Cawthon RM. Telomere measurement by quantitative PCR. Nucleic Acids Res 2002; 30(10): e47.
  32. Armanios M. Syndromes of telomere shortening. Annu Rev Genomics Hum Genet 2009; 10: 45-61.
  33. Kheirollahi M, Mehrazin M, Kamalian N, Mohammadi-asl J, Mehdipour P. Telomerase activity in human brain tumors: astrocytoma and meningioma. Cell Mol Neurobiol 2013; 33(4): 569-74.
  34. Slatter T, Gifford-Garner J, Wiles A, Tan X, Chen YJ, MacFarlane M, et al. Pilocytic astrocytomas have telomere-associated promyelocytic leukemia bodies without alternatively lengthened telomeres. Am J Pathol 2010; 177(6): 2694-700.
  35. Tabori U, Vukovic B, Zielenska M, Hawkins C, Braude I, Rutka J, et al. The role of telomere maintenance in the spontaneous growth arrest of pediatric low-grade gliomas. Neoplasia 2006; 8(2): 136-42.
  36. Royds JA, Al NS, Wiles AK, Chen YJ, Ahn A, Shaw A, et al. The CDKN2A G500 allele is more frequent in GBM patients with no defined telomere maintenance mechanism tumors and is associated with poorer survival. PLoS One 2011; 6(10): e26737.
  37. Durant ST. Telomerase-independent paths to immortality in predictable cancer subtypes. J Cancer 2012; 3: 67-82.
  38. Fajkus J. Detection of telomerase activity by the TRAP assay and its variants and alternatives. Clin Chim Acta 2006; 371(1-2): 25-31.
Journal of Isfahan Medical School
Volume 32, Issue 317 - Serial Number 317
November and December 2015
Pages 2333-2342

Files

History

  • Receive Date: 05 December 2014
  • Revise Date: 01 November 2024
  • Accept Date: 06 April 2022

Share

How to cite

Statistics